Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
June 11 2025 - 7:00AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company, today announced preclinical data
highlighting the potential of soquelitinib to treat systemic
sclerosis will be presented today in a poster session at the
European Alliance of Associations for Rheumatology (EULAR) 2025
Congress, which is taking place June 11-14, 2025 in Barcelona. The
poster will be presented by Gonçalo Boleto, M.D., MSc, a
rheumatologist at Centro Académico de Medicina de Lisboa, Portugal.
It was selected as a top 10 abstract by the Emerging EULAR Network
(EMEUNET), a network of young rheumatologists and researchers in
the field of rheumatology in Europe and beyond.
“There continues to be strong interest in the potential of ITK
inhibition to provide a new approach to treating a broad range of
diseases, including immune mediated fibrotic diseases such as
systemic sclerosis,” said Richard A. Miller, M.D., co-founder,
president and chief executive officer of Corvus. “We look forward
to presenting preclinical data to the audience at EULAR
demonstrating that soquelitinib, our lead ITK inhibitor, may
prevent lung damage, inflammation and pulmonary hypertension caused
by systemic sclerosis. While our main focus is developing
soquelitinib via our registration Phase 3 trial in peripheral T
cell lymphoma and Phase 1 trial in atopic dermatitis, we may
explore the potential of ITK in systemic sclerosis in future
clinical trials or via partnerships.”
Part of the preclinical data being presented at EULAR was
previously presented at ACR Convergence 2024, the annual meeting of
the American College of Rheumatology.
About Corvus PharmaceuticalsCorvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
pioneering the development of ITK inhibition as a new approach to
immunotherapy for a broad range of cancer and immune diseases. The
Company’s lead product candidate is soquelitinib, an
investigational, oral, small molecule drug that selectively
inhibits ITK. Its other clinical-stage candidates are being
developed for a variety of cancer indications. For more
information, visit www.corvuspharma.com or follow the Company
on LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements related to the potential of the
Company’s product candidates including soquelitinib, the potential
of ITK in systemic sclerosis in future clinical trials or via
partnerships, and continued advancement of the Company’s clinical
pipeline. All statements other than statements of historical fact
contained in this press release are forward-looking statements.
These statements often include words such as “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may”
or similar expressions. Forward-looking statements are subject to a
number of risks and uncertainties, many of which involve factors or
circumstances that are beyond the Company’s control. The Company’s
actual results could differ materially from those stated or implied
in forward-looking statements due to a number of factors, including
but not limited to, risks detailed in the Quarterly Report on Form
10-Q for the first quarter ended March 31, 2025, filed with the
Securities and Exchange Commission on May 8, 2025, as well as other
documents that may be filed by the Company from time to time with
the Securities and Exchange Commission. In particular, the
following factors, among others, could cause results to differ
materially from those expressed or implied by such forward-looking
statements: the Company’s ability to demonstrate sufficient
evidence of efficacy and safety in its clinical trials of its
product candidates; the accuracy of the Company’s estimates
relating to its ability to initiate and/or complete preclinical
studies and clinical trials and release data from such studies and
clinical trials; the results of preclinical studies and interim
data from clinical trials not being predictive of future results;
the Company’s ability to enroll sufficient numbers of patients in
its clinical trials; the unpredictability of the regulatory
process; regulatory developments in the United States and foreign
countries; the costs of clinical trials may exceed expectations;
and the Company’s ability to raise additional capital. Although the
Company believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee that
the events and circumstances reflected in the forward-looking
statements will be achieved or occur, and the timing of events and
circumstances and actual results could differ materially from those
projected in the forward-looking statements. Accordingly, you
should not place undue reliance on these forward-looking
statements. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:Leiv LeaChief Financial
OfficerCorvus Pharmaceuticals,
Inc.+1-650-900-4522llea@corvuspharma.com
MEDIA CONTACT:Sheryl SeapyReal
Chemistry+1-949-903-4750sseapy@realchemistry.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Jun 2025 to Jul 2025
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Jul 2024 to Jul 2025